RECRUITING

UPLYFT For Lymphoma Survivors

Talk to us

Conditions

LymphomaSurvivorship

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The main purpose of this study is to field test and pilot an intervention called UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) that includes information about lymphoma survivorship and tools to improve quality of life and reduce lymphoma-related worries among lymphoma survivors.

Official Title

An Intervention for Fear of Cancer Recurrence for Lymphoma Survivors

Quick Facts

Study Start:2022-02-08
Study Completion:2025-04-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05080166

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Diagnosis of lymphoma (indolent non-Hodgkin lymphoma, aggressive non-Hodgkin lymphoma, or classic Hodgkin lymphoma)
  2. * Age ≥ 18 years
  3. * Interval of 3 months to 24 months from completion of first-line treatment
  4. * In complete remission after first line of treatment
  5. * Clinically significant FCR (score of ≥ 16 on the validated FCR Inventory-Severity Subscale \[FCRI-SS).
  6. * Access to computer (for videoconferencing)
  7. * Lymphoma clinicians ≥ 1 year from oncology fellowship completion OR mental health clinicians (psychologists, social workers, psychiatrists) ≥ 1 year from completion of clinical training.
  8. * Longitudinal clinical care for patients with lymphoma by oncologists OR provision of care for patients with cancer by mental health clinicians
  1. * Age \< 18 years
  2. * Concurrent other malignancy
  3. * Patients with uncontrolled/untreated psychotic disorders or untreated bipolar and borderline personality disorder (as ascertained from medical record screen).
  4. * Age \< 18 years
  5. * Concurrent other malignancy
  6. * Patients with uncontrolled/untreated psychotic disorders or untreated bipolar and borderline personality disorders (as ascertained from medical record screen).
  7. * Our study will exclude members of the following special populations:
  8. * Adults unable to consent
  9. * Individuals who are not yet adults (infants, children, teenagers)
  10. * Pregnant women
  11. * Prisoners

Contacts and Locations

Study Contact

Oreofe O Odejide, MD, MPH
CONTACT
(617) 632-6864
Oreofe_Odejide@dfci.harvard.edu

Principal Investigator

Oreofe O Odejide, MD, PhD
PRINCIPAL_INVESTIGATOR
Oreofe_Odejide@dfci.harvard.edu

Study Locations (Sites)

Dana-Farber Cancer Institute
Boston, Massachusetts, 02215
United States

Collaborators and Investigators

Sponsor: Dana-Farber Cancer Institute

  • Oreofe O Odejide, MD, PhD, PRINCIPAL_INVESTIGATOR, Oreofe_Odejide@dfci.harvard.edu

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-02-08
Study Completion Date2025-04-30

Study Record Updates

Study Start Date2022-02-08
Study Completion Date2025-04-30

Terms related to this study

Keywords Provided by Researchers

  • Lymphoma
  • Survivorship

Additional Relevant MeSH Terms

  • Lymphoma
  • Survivorship